Literature DB >> 20701625

Lipid assessment, metabolic syndrome and coronary heart disease risk.

Benoit J Arsenault1, Jean-Pierre Després, Erik S G Stroes, Nicholas J Wareham, John J P Kastelein, Kay-Tee Khaw, S Matthijs Boekholdt.   

Abstract

BACKGROUND: Although the total to high-density lipoprotein cholesterol ratio (TC/HDL-C) has been used for decades to identify individuals at risk for coronary heart disease (CHD), apolipoprotein-based (apolipoprotein B/apolipoprotein A-I [apoB/apoA-I]) and nuclear magnetic resonance spectroscopy (NMR)-based lipoprotein concentrations (low-density lipoprotein(NMR) /high-density lipoprotein(NMR) [LDL(NMR) /HDL(NMR)]) may also be useful for CHD risk stratification.
MATERIALS AND METHODS: In a case-control study conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study population, 870 individuals who developed CHD during a 6-year follow-up were matched to 1659 controls on the basis of gender, age and enrollment time. LDL(NMR) and HDL(NMR) were measured by proton NMR spectroscopy.
RESULTS: After adjusting for traditional CHD risk factors, men in the top quintile of the various lipoprotein ratios proved to be at increased CHD risk (OR = 2·59 [95% IC, 1·76-3·83] for TC/HDL-C ratio, 2·59 [1·75-3·83] for apoB/apoA-I ratio and 2·78 [1·86-4·17] for LDL(NMR) /HDL(NMR) ratio) compared with men in the bottom quintile. Similar associations were observed in women (OR = 2·86 [1·71-4·80] for TC/HDL-C ratio, 2·94 [1·74-4·97] for apoB/apoA-I ratio and 2·03 [1·21-3·43] for LDL(NMR)/HDL(NMR) ratio). Compared with participants with only one component of the metabolic syndrome, those who had five had an increased TC/HDL-C ratio (73·0% and 80·4% in men and women respectively), apoB/apoA-I ratio (58·0% and 62·9% in men and women respectively) and for LDL(NMR)/HDL(NMR) ratio (52·6% and 54·1% in men and women respectively).
CONCLUSION: In this European study population, the TC/HDL-C, apoB/apoA-I and LDL(NMR) /HDL(NMR) ratios were similarly associated with components of the metabolic syndrome and CHD risk.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20701625     DOI: 10.1111/j.1365-2362.2010.02357.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

Review 1.  Lipid parameters for measuring risk of cardiovascular disease.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

2.  Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.

Authors:  Rutger Verbeek; Marjorie Boyer; S Matthijs Boekholdt; G Kees Hovingh; John J P Kastelein; Nicholas Wareham; Kay-Tee Khaw; Benoit J Arsenault
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-11-17       Impact factor: 8.311

3.  Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review.

Authors:  Paramjit K Sandhu; Salma M A Musaad; Alan T Remaley; Stephanie S Buehler; Sonya Strider; James H Derzon; Hubert W Vesper; Anne Ranne; Colleen S Shaw; Robert H Christenson
Journal:  J Appl Lab Med       Date:  2016-08-01

4.  Association between Serum Cholesterol Level and Bone Mineral Density at Lumbar Spine and Femur Neck in Postmenopausal Korean Women.

Authors:  Jeong-Ho Go; Yun-Mi Song; Joo-Hyun Park; Jae-Young Park; Yun-Ho Choi
Journal:  Korean J Fam Med       Date:  2012-05-24

5.  Alternative waist-to-height ratios associated with risk biomarkers in youth with diabetes: comparative models in the SEARCH for Diabetes in Youth Study.

Authors:  Henry S Kahn; Jasmin Divers; Nora F Fino; Dana Dabelea; Ronny Bell; Lenna L Liu; Victor W Zhong; Sharon Saydah
Journal:  Int J Obes (Lond)       Date:  2019-03-29       Impact factor: 5.551

6.  Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intake.

Authors:  Gianluca Tognon; Christina Berg; Kirsten Mehlig; Dag Thelle; Elisabeth Strandhagen; Jaana Gustavsson; Annika Rosengren; Lauren Lissner
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

Review 7.  Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values.

Authors:  Robert S Rosenson; James A Underberg
Journal:  Cardiovasc Drugs Ther       Date:  2013-10       Impact factor: 3.727

8.  Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.

Authors:  Ruben N Eppinga; Minke H T Hartman; Dirk J van Veldhuisen; Chris P H Lexis; Margery A Connelly; Erik Lipsic; Iwan C C van der Horst; Pim van der Harst; Robin P F Dullaart
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

Review 9.  Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

Authors:  Margery A Connelly; Jonathan Velez Rivera; John R Guyton; Mohammad Shadab Siddiqui; Arun J Sanyal
Journal:  Aliment Pharmacol Ther       Date:  2020-07-08       Impact factor: 9.524

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.